Here's my summary of key studies presented Tuesday.
Tofacitinib in Polyarticular JIA
Flares of vasculitis can still be a problem after hepatitis C-related cryoglobulinemic vasculitis patients are cured of their hepatitis C by direct-acting antivirals, as demonstrated by data from four registries presented at ACR 2019 in Atlanta, Georgia.
Shingrix (GSK), the herpes zoster subunit vaccine (a two-shot series), was approved by the FDA in Fall 2018 and is currently approved for use in adults 50 years and older.
It has been a wonderful year for autoinflammatory diseases at the ACR Annual Meeting.
Sunday was the first full day of scientific sessions at the 2019 ACR/ARP meeting in Atlanta. Yesterday we shared our initial news articles, videos and more with you. Following is my roundup of day one.
Delays in Diagnosis
Many rheumatic diseases affect women of childbearing age. In the age of biologic therapy, women are achieving better disease activity and there are increasing numbers of women with rheumatic diseases attempting pregnancy.
I have been attending the ACR Review Course for more than a decade, and it seems every year it gets better and better. Contrary to what most people think, this is not a board review course; it is more of a review of the latest research delivered by experts condensing rheumatology in eig
Like many rheumatologists who are headed to the 2019 American College of Rheumatology meeting in Atlanta, I am eagerly looking forward to learning about the new criteria in vasculitis, lupus, and autoinflammatory recurrent fevers. Yet conference attendees should remember that these crit